How long does Repatha (evolocumab) take to lower Low-Density Lipoprotein (LDL) cholesterol levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How Long Before Repatha Works

Repatha (evolocumab) begins lowering LDL cholesterol within 4 weeks of initiation, with peak LDL-C reduction occurring approximately 1 week after each 140 mg dose (given every 2 weeks) or 2 weeks after each 420 mg dose (given monthly). 1, 2

Onset of Action

  • The FDA label states that the LDL-lowering effect of Repatha may be measured as early as 4 weeks after initiation. 1

  • The pharmacodynamic effects on PCSK9 are rapid, with maximum PCSK9 suppression occurring within 4 hours of administration. 2

  • At steady state, peak LDL-C reduction occurs approximately 1 week after a subcutaneous dose of 140 mg every 2 weeks and 2 weeks after a 420 mg monthly dose. 2

Magnitude of LDL-C Reduction

  • Evolocumab reduces LDL-C by approximately 59-64% when added to maximally tolerated statin therapy. 3

  • In the FOURIER trial, baseline median LDL-C of 92 mg/dL was reduced by 59% to a median value of 30 mg/dL at 48 weeks. 3, 4

  • Both the 140 mg every 2 weeks and 420 mg monthly regimens provide comparable LDL-C reduction (64% and 58% respectively). 3, 5

Peak and Trough Effects

  • Peak LDL-C reduction is approximately 73% for the 140 mg every 2 weeks regimen and 69% for the 420 mg monthly regimen. 6

  • LDL-C levels return toward baseline over the dosing interval, with median peak-trough variability of approximately 20.5% for 140 mg every 2 weeks and 21.1% for 420 mg monthly. 6

  • When monitoring LDL-C for patients receiving 420 mg monthly, the FDA recommends measuring LDL-C just prior to the next scheduled dose, as LDL-C can vary during the dosing interval. 1

Clinical Implications

  • The rapid onset allows for relatively quick assessment of treatment response, with meaningful LDL-C measurements possible at 4 weeks. 1

  • The sustained LDL-C reduction with approved doses (140 mg every 2 weeks or 420 mg monthly) provides greater stability compared to lower doses. 6

  • For patients with homozygous familial hypercholesterolemia, if a clinically meaningful response is not achieved in 12 weeks with 420 mg monthly, the dose can be increased to 420 mg every 2 weeks. 5, 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Repatha (Evolocumab) Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.